-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
【Pharmaceutical Network Conference Forum】Traditional pharmaceutical enterprises often have defects such as low production efficiency and low production management level, and the rapid development of the domestic pharmaceutical industry, as well as the background of price reduction, medical insurance control costs, and labor costs rising year by year, the traditional production model has been difficult to adapt to the needs of large-scale production of pharmaceutical companies, and it is difficult to meet the increasingly stringent regulatory requirements of
the pharmaceutical industry.
With the development of cloud computing, 5G, Internet, big data and other technologies, in the wave of manufacturing changes, digital transformation has become the direction
that many pharmaceutical companies are exploring.
However, how to successfully carry out digital transformation is a major issue
facing biomedical companies.
Compared with other manufacturing industries, the biomedical industry belongs to a special industry related to human health and safety, so the safety and quality of drugs are also facing higher requirements, which also makes pharmaceutical companies relatively cautious
in carrying out digital layout.
According to data statistics from the National Industrial Information Security Development Research Center, more than half of pharmaceutical companies are still in the state of single point informatization and digital coverage, and the integration between systems is low, and 26% of pharmaceutical manufacturing enterprises are still in the initial stage
of digitalization.
The industry pointed out that security, compliance is a problem that pharmaceutical companies must consider in digital construction, because pharmaceutical companies need and have a large number of data such as research and development data, clinical data, etc.
, need to meet domestic and foreign data security related standards, take the compliance development route, this aspect will bring great challenges
to pharmaceutical companies.
In view of the efficient and compliant production needs of the pharmaceutical industry, at 15:00 on October 13, 2022, Wang Peidong, General Manager of Schneider Electric's Industrial Automation Business / Life Sciences Industry, will be a guest of the pharmaceutical network live broadcast room, bringing a live classroom with the theme of "Achieving Efficient and Compliant Pharmaceutical Production with Open Lifecycle Digital Means", combined with Schneider Electric's full-life cycle digital solutions, hoping to provide a "best practice" for the majority of pharmaceutical companies! Scan the QR code above to make an appointment [About Schneider Electric] Schneider Electric's purpose is to empower everyone to make greater use of energy and resources, and promote human progress and sustainable common development
.
Our mission is to be your digital partner for efficiency and sustainability
.
We drive digital transformation to serve the home, building, data center, infrastructure and industrial markets
.
Through integrated process and energy management technologies, we interconnect products, controls, software and services from the end to the cloud to achieve integrated enterprise management
throughout the entire business lifecycle.
We are a global company with localization strengths, committed to promoting an open technology and partner ecosystem, and actively practicing the shared values
of meaningfulness, inclusion and empowerment.